Bipolar disorder (BD) is a highly heritable mood disorder with complex genetic architecture and 24 poorly understood etiology. We performed a whole blood transcriptome analysis in a BD case-25 control sample (Nsubjects = 480) by RNA sequencing. While we observed widespread differential 26 gene expression patterns between affected and unaffected individuals, these effects were largely 27 linked to lithium treatment at the time of blood draw (FDR < 0.05, Ngenes = 976) rather than BD 28 diagnosis itself (FDR < 0.05, Ngenes = 6). These lithium-associated genes were enriched for cell 29 signaling and immune response functional annotations, among others, and were associated with 30 neutrophil cell-type proportions, which were elevated in lithium users. Neither genes with altered 31 expression in cases nor in lithium users were enriched for BD, schizophrenia, and depression 32 genetic risk based on information from genome-wide association studies, nor was gene 33 expression associated with polygenic risk scores for BD. Our findings suggest that BD is 34 associated with minimal changes in whole blood gene expression independent of medication use 35 but underline the importance of accounting for medication use and cell type heterogeneity in 36 psychiatric transcriptomic studies. The results of our study add to mounting evidence of lithium's 37 cell signaling and immune-related mechanisms. 38 39
Introduction 40
Bipolar disorder (BD) is a chronic and recurrent psychiatric disorder affecting approximately 1% 41 of the population worldwide and presenting a major public health burden 1,2 . It is characterized 42 clinically by instability in mood resulting in manic and depressive episodes interspersed between 43 neutral, euthymic states 2 . Risk for BD is highly genetic, with heritability estimates as high as 85% Table 1 we present a summary that reveals a lack of consistency between findings likely 49 owing to clinical heterogeneity, differing study designs, and the low numbers of samples 50 investigated (N ≤ 62 BD subjects) . Moreover, there are many potential confounds that impact 51 gene expression, including medication. 52 Therefore, to explore gene expression changes associated with BD, we generated RNA 53 sequencing data from peripheral whole blood collected in a large, well-characterized case-control 54 cohort from The Netherlands. We examined gene expression differences between groups both at 55 the individual gene level and at the level of gene co-expression. Upon correction for technical and 56 biological variables including the use of lithium, the most widely used prescription drug in our 57 cohort, gene expression differences between subjects with BD and controls were minor. 58
Differences in subjects being treated with lithium compared to those who are not, however, were 59 widespread. These differences were partially but not entirely explained by differences in cell-type 60 composition, driven by elevated neutrophil proportions in lithium users. The lithium-associated 61 changes in gene expression were independent of psychiatric genetic risk, though. Our results 62 suggest nominal BD-related gene expression effects in blood but numerous effects related to 63 lithium treatment. This work highlights the importance of accounting for medication use in 64 psychiatric transcriptomic studies and provides insight into lithium's molecular mechanisms of 65 action. 66 67
Methods 68
Sample preparation and RNA sequencing 69 See Supplementary Methods for more information regarding sample ascertainment and 70 assessment. Peripheral whole blood was drawn and processed for genotyping and RNA 71 sequencing from 240 controls and 240 cases, of whom 227 (94.6%) had a diagnosis of bipolar I 72 6 variables: age, sex, lithium use, tobacco use, assessment group, RIN, sequencing plate, and 123 sequencing metric PCs 1 through 3. The final covariate model for DEGs between subjects being 124 treated with lithium (i.e. lithium users) and non-lithium users included the following variables: BD 125 diagnosis, age, sex, tobacco use, assessment group, RIN, sequencing plate, and sequencing 126 metric PCs 1 through 3. Tobacco use was included because of its well-characterized effect on 127 whole blood gene expression 30 . An overview of covariates can be found in Table S1 . 
Minimal changes in bipolar disorder gene expression 255
To explore the transcriptomic signatures of BD, we first evaluated whether subjects with BD 256 harbored transcriptional differences on a per gene level compared with controls. Of the 12,344 257 genes tested, only six were differentially expressed in BD after correcting for multiple testing (FDR 258 < 0.05; Figure 1A ). The differences in expression were very small, with absolute fold changes 259 ranging from 0.12 to 0.44. While the number of identified differentially expressed genes (DEGs) 260 was too small to perform functional enrichment analysis, we did find that three of the six genes 261 (COG4, DOCK3, and BBS9) were expressed in GTEx frontal cortex tissue (median TPM > 1) and 262
show relatively stable expression across brain cell types except for DOCK3, which is enriched in 263 neurons (fold change relative to other cell types = 6.82; Table S3 ). Four of the genes were present 264 in the Stanley Genomics brain gene expression database, and two of these were found to be 265 differentially expressed in BD individuals in at least one study, COG4 and DOCK3, although the 266 latter was altered in the opposite direction. COG4 was also reported as differentially expressed in 267 a schizophrenia mega-analysis of nine whole blood microarray datasets 21 . Using polygenic risk 268 scores (PRS) for BD as the differential expression trait of interest rather than the dichotomous 269 case-control phenotype did not yield any significant genes, even though PRS did significantly 270 differ between BD cases and controls (t = -3.42, P = 6.88 x 10 -4 ; Figure S1 ; To validate our results, the 976 lithium-use DEGs were tested for overlap with lists of 287
DEGs from similar studies found in the literature (Table S4 ). Although none of these studies has 288 the same design as ours, we did find a significant overlap between our 976 lithium-use DEGs and 289 the lists from two studies. In the first study 18 , DEGs were detected by comparing peripheral 290 monocyte gene expression in subjects before and after lithium monotherapy. Of the 35 DEGs 291 discovered, 18 were shared with the current study (hypergeometric odd ratio (OR) = 13.57, P = 292 4.66 x 10 -12 ), and all 18 were concordant in direction ( Figure S2A ). In the second study 19 , DEGs 293 were detected by comparing LCL gene expression before and after lithium treatment in vitro. Of 294 the 1,504 DEGs discovered, 134 were shared with our study (hypergeometric OR = 1.27, P = 295 9.23 x 10 -3 ), and 84.6% of these were concordant in direction ( Figure S2B ). There were two genes 296 shared between all three lists, RFX2 and SLC29A1. We report genes in these overlapping lists 297 as high confidence lithium-associated genes (Supplementary File 1) . 298
299
Modules of co-expressed genes are associated with lithium use 300 Next, in search of genes with differential co-expression in BD, we constructed a gene expression 301 network in the entire sample using WGCNA and assessed the detected modules for association 302 with BD. This network consisted of 27 modules ranging in size from 48 to 2,760 genes (mean 303 (Table  307 S5). Of the five modules associated with lithium use, three shared significant overlap with lithium-308 use DEGs (Table 2) . M26 was most significantly associated with lithium (P = 2.00 x 10 -4 ; Figure  309 S3A) but was not significantly enriched for lithium DEGs. M1 was also associated with lithium (P 310 = 9.04 x 10 -4 ; Figure S3B ) and had the most significant enrichment of DEGs (431 of 2,092 genes 311 in the module were DEGs; hypergeometric OR = 4.62, P = 2.03 x 10 -97 ). Functional annotation 312 clustering of the genes in M1 showed an enrichment of terms related to cell signaling, immunity, 313 and glycophosphatidylonositol anchor. 314
Module preservation analysis was also performed to assess differences in network density 315 and connectivity between groups, but showed full preservation indicating that networks 316 constructed in separate groups maintain their underlying structure (Supplementary Methods and 317 Figure S4 ). 318
319

Estimated neutrophil proportions are increased in lithium users 320
We then sought to determine if variation in our sample could be explained by differences in blood 321 cell-type composition. To deconvolve cellular heterogeneity, we applied CIBERSORT 33 to our 322 gene expression quantifications using a reference panel of 22 blood cell-type signatures. The 323 resulting estimated cell-type proportions ( Figure 2A We then sought to determine if the various lithium-associated modules of co-expressed genes 341 reflected biologic signatures of distinct populations of blood cell types. We did this in two ways. 342
First, a hypergeometric overlap between lithium-associated module gene lists and cell-type 343 signature gene lists revealed a significant overlap between module M1 with monocyte and 344 neutrophil signature genes and M9 with eosinophil and activated mast cell signature genes( Figure 3A, left) . Second, the expression of cell-type signature genes was used to predict module 346 membership values in a linear model for each of the five lithium-associated modules. Neutrophils, 347 monocytes, and eosinophils were again implicated ( Figure 3A, right) . In both of these analyses, 348 the most significant cell type-module relationship was M1 with neutrophil estimates 349 (hypergeometric P = 5.68 x 10 -21 , linear model P < 2.20 x 10 -16 ). Indeed, neutrophil signature 350 genes had higher M1 membership values ( Figure 3B) . 351
352
Genes with altered expression are not enriched for genes with common psychiatric risk alleles 353
To evaluate if BD and lithium-use DEG sets were associated with a higher burden of psychiatric 354 risk alleles, we performed gene-set analyses using MAGMA 34 . Analyses were performed across 355 three psychiatric GWAS traits: BD 36 , SCZ 35 , and self-reported depression 37 . SCZ and depression 356
were used because of their high degree of overlap in SNP-based heritability with BD 4 (Table S6) . Table S7 ). Because sleep disturbances are a hallmark 365 of BD 39 , and due to the genetic correlation of sleep-related phenotypes with BD 40 , we performed 366 a secondary gene-set analysis with genes implicated from chronotype, sleep duration, 367 oversleeping, and undersleeping GWAS, which failed to demonstrate association with genes 368 identified in the current study (Table S8) . 369
Discussion 371
In our whole blood BD case-control gene expression study we observed widespread subtle 372 changes in gene expression in subjects undergoing lithium treatment but few transcriptomic 373 differences linked to disease status. These effects were partially driven by variation in leukocyte 374 cell type composition, and we find no evidence for a link with genetic risk for BD. Upon validation 375 of our findings with previous in vivo and in vitro lithium treatment gene expression studies, we 376 present a high-confidence list of genes that display altered expression associated with lithium 377 treatment. 378
One of the top differentially expressed genes associated with BD, COG4, encodes a part 379 of a multiprotein complex that is a key determinant of Golgi apparatus structure and capacity for 380 intracellular transport and glycoprotein modification 41 . COG4 mRNA is expressed widely across 381 body tissues including the brain 42 . It has been reported as having alternative splicing in subjects 382 with BD 43 , and concordant with our results, was reported as down-regulated in three of the ten 383
Stanley Genomics BD brain datasets 44 . Further work is needed to determine the role of COG4 in 384 BD, but perhaps neuronal hyperexcitability in BD 16 destabilizes internal cellular processes 385 including Golgi function 45 . There is currently no evidence for a genetic link between BD disease 386 susceptibility and COG4
. 387
Lithium is the first-line treatment for BD, not only for the treatment of acute episodes but 388 also for maintenance and suicide prevention 46, 47 . However, only about 30% of BD patients fully 389 respond to lithium, it has several adverse side effects, and its mechanisms of action are not well 390 understood [48] [49] [50] . One probable reason for this lack of understanding is the magnitude of lithium's 391 physiological interactions 51 . In pharmacological terms, lithium is a small molecule (the third 392 smallest element in fact) without a defined target 50 . This lack of specificity makes it difficult to 393 discern therapeutic mechanisms from off-target effects, which likely lead to many of lithium's 394 undesirable side effects and even its toxicity at doses that are too high. Lithium ions (Li factors like body mass index or smoking. These results contribute to the understanding of the 418 genomics of lithium action, which may be essential for the future of personalized psychiatric 419 medicine for patients with BD. Future studies with larger sample sizes and independent replicationdatasets will be needed to confirm our findings, and whether these genes and pathways play a 421 role in the mood-stabilizing mechanisms of lithium remains to be determined. 422
The lack of enrichment of genetic signal from common alleles associated with BD, 423 schizophrenia, or self-reported depression suggests that genes transcriptionally associated with 424 lithium treatment in peripheral blood most likely represent secondary effects of treatment that are 425 independent from disease susceptibility. The lack of genetic enrichment could also indicate that 426 our gene expression study is underpowered for this purpose, or that the transcriptomic 427 mechanisms of genetic risk for BD are not present in whole blood. In addition, the currently 428 available GWAS may still be underpowered thereby impacting our ability to detect a significant 429 enrichment. With the expected rapidly increasing sample sizes of these GWAS studies we will be 430 able to test this hypothesis more fully in the near future. We did explore the opportunity to examine 431 enrichment of genetic susceptibility of lithium response, but because this phenotype has a SNP-432 based heritability not different from zero, this specific analysis is not meaningful. In this regard, it 433 is important to distinguish between lithium use, the phenotype we used in our study, and lithium 434 response. Self-reported answers to a lithium questionnaire by participants in our study show that 435 the majority of subjects being treated with lithium had a positive response to the treatment and 436 the majority of non-users have been treated with lithium in the past (Supplementary Methods). 437 We therefore consider that the lithium use phenotype partially captures lithium response, but 438 disentangling the complex interplay between these phenotypes is an avenue for further 439 exploration. 440
Lithium use, as a trait only present in BD subjects and therefore confounded with BD 441 diagnosis, serves as a confounder by indication and likely eliminated most of the observable BD 442 effects. Our results highlight the importance of correcting for cell type composition as well as 443 medication use in BD transcriptome studies. A lithium-naive study design is warranted to optimize 444 transcriptome in whole blood remains valuable for the following reasons. It is an accessible tissue, 446 it has the potential for biomarker discovery, and it can be used in longitudinal study designs, which 447 are appealing due to the episodic nature of BD. It may also be a choice tissue to observe the 448 suggested immune component of BD etiology. In addition, peripheral tissues such as blood 449 partially recapitulate gene expression signatures of the brain 58 , and compared to post-mortem 450 tissues are less subject to poor quality due to rapid degradation upon death 59 . However, studies 451 involving post-mortem tissue, in vitro neuronal cells, or animal models will still be needed to 452 determine the therapeutic effect of lithium on BD-associated brain-related function. BD GWAS 36 , PGC schizophrenia GWAS 35 , and 23andMe self-reported depression GWAS 37 ) 512 using MAGMA 34 . DEG sets stratified by up-and down-regulated genes. The BD DEG set was 513 extended to include genes with FDR-corrected P < 0.2. The positive control gene-set consisted 514 of the top 100 most significant genes from a random draw of N = 1,000 using the BD GWAS gene-515 level test statistics. The positive control gene-set association with BD was highly significant (P = 516 1.28 x 10 -27 ) but the -log10 P-value was limited to 3 in the plot. The negative control gene-set 517 consisted of a random draw of N = 1,000 genes using the BD GWAS gene-level test-statistics. 518
The red line represents the significance threshold of -log10(0.05). All P-values and effect sizes are 519 reported in Table S7 . 520
